A novel and safe approach for treating cognitive disorders
January 17, 2023Umecrine Cognition announces Orphan Drug Designation granted by FDA for golexanoloneSTOCKHOLM – January 17, 2023. Umecrine Cognition AB today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
January 9, 2023Umecrine Cognition will attend the JP Morgan 41st Annual Healthcare Conference 2023 in San FranciscoSTOCKHOLM – January 9, 2023. Umecrine Cognition today announces that the company will attend the JP Morgan 41st Annual Healthcare Conference in San...
January 3, 2023Umecrine Cognition presents data showing improved symptoms in a model of Parkinson’s disease following treatment with golexanoloneStockholm, January 3, 2023 – Umecrine Cognition AB today announced results showing that the company’s clinical drug candidate golexanolone...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.